5 results
To investigate the efficacy, safety, and pharmacokinetics of volasertib in combination with low-dose cytarabine versus investigator*s choice of anti-leukemic treatment in patients with relapsed or refractory acute myeloid leukemia with no…
The aim of this study is to assess the effectivity of the Fluxion, in combination with Bluem (Bluem, Bluem Europe, Zwolle, The Netherlands) and in combination with demineralised water. This aims to find a minimally invasive treatment for peri-…
To investigate the efficacy, safety, and pharmacokinetics of intravenous volasertib + subcutaneous low-dose cytarabine in patients * 65 years of age with previously untreated acute myeloid leukaemia, ineligible for intensive remission induction…
The objective is to define the maximum tolerable dose (MTD) by evaluation of dose-limiting toxicity (DLT) of volasertib in paediatric leukaemia and solid tumours in the age group 2 to less than 12 and 12 to less than 18 years. A further objective is…
The primary goal of this study is to investigate whether placebo-controlled double-blind titration leads to optimizing the use of methylphenidate. This by detecting placebo-and non-responders more efficiently and by treating responders better so…